XNK Therapeutics appoints Dr. Peter Hovstadius as CMO
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr. Hovstadius will be a member of the company’s management team. Dr. Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor.Dr. Hovstadius received his MD from Uppsala University in 1992 and his PhD in Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment in 2005. He is also a specialist in Clinical Pharmacology. During his career, he has held Medical Director